NVAX

Novavax, Inc.

A maker of protein-based vaccines against infectious diseases, this Maryland biotech is best known for Nuvaxovid, its COVID-19 shot that delivers pre-made spike proteins grown in moth cells rather than genetic instructions. Founded in 1987 and spun off from its parent IGI in 1995, it gained its Matrix-M immune-boosting adjuvant by buying Sweden's Isconova in 2013. The name blends "nova" (new) with "vax" (vaccine).

CUSIP: 670002104HealthcareUS1 holder

Ownership Activity Financials Filings

NVAX

NVAX

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Regulation FD Disclosure